title: Hazards of interferon therapy for HBV-seronegative chronic hepatitis.
authors.forename: S
authors.initials: S
authors.lastname: Vento
authors.forename: G
authors.initials: G
authors.lastname: Di Perri
authors.forename: T
authors.initials: T
authors.lastname: Garofano
authors.forename: L
authors.initials: L
authors.lastname: Cosco
authors.forename: E
authors.initials: E
authors.lastname: Concia
authors.forename: T
authors.initials: T
authors.lastname: Ferraro
authors.forename: D
authors.initials: D
authors.lastname: Bassetti
mesh_terms: D000293:Adolescent; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D006526:Hepatitis C / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D006510:Hepatitis B Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins